full
border
#666666
https://www.arboretumvc.com/wp/wp-content/themes/zap-installable/
https://www.arboretumvc.com/wp/
#ffffff
style1

Archive for May, 2014

28
May

St. Jude Medical, Inc., a global medical device company, and CardioMEMS, today announced U.S. Food and Drug Administration (FDA) approval of the CardioMEMS™ HF System. The CardioMEMS HF System is the first and only FDA-approved heart failure (HF) monitoring device that has been proven to significantly reduce HF hospital admissions when used by physicians to manage heart failure.

Link

0 Comments
28
May

Tangent Medical, an innovator of IV therapy products, announced it has received CE Mark approval for the NovaCath™ Integrated IV Catheter System. The approval demonstrates that NovaCath meets the safety, health and environmental requirements in the European Union and clears the company to introduce NovaCath throughout Europe and other countries recognizing the CE Mark.

Download PDF

0 Comments
20
May

Advanced ICU Care, a leading national provider of remote tele-ICU monitoring services, was recognized as the winner in the Clinical Effectiveness category at TripleTree’s 6th Annual iAward for Connected Health competition, a part of the Wireless-Life Sciences Alliance (WLSA) Convergence Summit held in San Diego on May 15 and 16, 2014. iAward participants and winners were selected based on demonstrated insight, innovation and initiative in connected health.

Download PDF

16
May

Jeff Williams is one of Michigan’s most successful biotech entrepreneurs, with two of Michigan’s biggest exits—Accuri and Handylab—on his ledger. Now he’s hoping the third time’s a charm, too.  Williams’ new molecular diagnostic start-up, NeuMoDx,  just closed a $21 million Series B round in April.

Link

 

0 Comments
14
May

Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provided ETC-1002 development program updates and financial results for the first quarter ended Mar. 31, 2014.

Download PDF

0 Comments
02
May

Esperion Therapeutics, Inc. (Nasdaq: ESPR) announced the company will deliver three posters featuring ETC-1002 Phase 2 clinical results at the 2014 Annual Scientific Sessions of the National Lipid Association in Orlando, Fla. The posters provide additional information from previously-presented Phase 2 studies of ETC-1002, and new analyses regarding blood pressure lowering in patients with both hypercholesterolemia and mildly elevated blood pressure.

Download PDF

0 Comments
1
1
scrollauto
Loading posts...
link_magnifier
#ffffff
on
loading
off